Plegridy
peginterferon beta-1a
Table of contents
Overview
Plegridy is a medicine used to treat multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. It is used specifically in adults with a type of MS known as relapsing-remitting MS, where the patient has flare-ups of symptoms (relapses) between periods of recovery (remissions).
Plegridy contains the active substance peginterferon beta-1a.
-
List item
Plegridy : EPAR - Medicine overview (PDF/121.59 KB)
First published: 31/07/2014
Last updated: 22/12/2020
EMA/652144/2020 -
-
List item
Plegridy : EPAR - Risk-management-plan summary (PDF/91.18 KB)
First published: 31/07/2014
Last updated: 23/03/2022
EMA/329000/2014
Authorisation details
Product details | |
---|---|
Name |
Plegridy
|
Agency product number |
EMEA/H/C/002827
|
Active substance |
peginterferon beta-1a
|
International non-proprietary name (INN) or common name |
peginterferon beta-1a
|
Therapeutic area (MeSH) |
Multiple Sclerosis
|
Anatomical therapeutic chemical (ATC) code |
L03AB13
|
Publication details | |
---|---|
Marketing-authorisation holder |
Biogen Netherlands B.V.
|
Revision |
23
|
Date of issue of marketing authorisation valid throughout the European Union |
18/07/2014
|
Contact address |
Prins Mauritslaan 13 |
Product information
30/03/2023 Plegridy - EMEA/H/C/002827 - II/0068
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunostimulants
Therapeutic indication
Treatment of relapsing remitting multiple sclerosis in adult patients.